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ABSTRACT 
Objectives: To determine whether patients who received Medication Therapy Management (MTM) from community pharmacists 
using a brief scale to measure Therapeutic Alliance (i.e., MTM + TA) would show better medication adherence than patients who 
received MTM without use of the TA scale (MTM only). Design: Quasi-experimental, using a direct intervention group (MTM + TA) 
and a comparison group of randomly selected claims records from patients who received only the MTM service (MTM only). We used 
a doubly robust propensity score approach to estimate the average effect of therapeutic alliance on medication adherence. The 
analysis was limited to the following broad medication categories: antihypertensives, antidiabetic agents, and antihyperlipidemics. 
Setting: The direct intervention group included patients receiving MTM services from pharmacists in a community pharmacy chain 
setting. Participants: After matching with claims data, the direct intervention group was n=117, with an average age of 76.4. The 
comparison group was n=146, with an average age of 76.2.  Intervention: Administration of two brief scales designed to measure 
general health outcomes and TA within the context of MTM (with focus on TA scale administration).  Main Outcome Measures 
Proportion of Days Covered (PDC) and PDC80. Results: Using the therapeutic alliance scales in the context of community pharmacist-
provided MTM was associated with a 3.1 percentage point increase in patients’ overall PDC (p<.001) and an increase of 4.6 
percentage points in PDC80 (p=.02) as compared to patients receiving MTM without use of the therapeutic alliance scales. 
Conclusion: Measuring therapeutic alliance in the context of MTM is associated with improved medication adherence and represents 
one strategy for enhancing the effectiveness of MTM encounters. Furthermore, administration of the therapeutic alliance scales used 
very little time; therefore it is likely feasible for pharmacists to routinely use the scales in their practice.  
 
 
Introduction  
Medication non-adherence, or deviating from the specific 
prescription of a physician or other prescribing healthcare 
provider, is a significant clinical issue.1 Numerous studies 
have found a relationship between non-adherence and worse 
health outcomes. For example, medication non-adherence in 
patients with diabetes mellitus is associated with greater risks 
of hospitalization and mortality.2 Non-adherence to 
antihypertensives is a contributing factor to persistent 
elevated blood pressure.3 Elderly persons have shown  
significant declines in adherence to statin therapies, which  
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can exacerbate or lead to clinical events associated with 
cardiovascular disease.4 Further, it is suggested that 
medication non-adherence may lead to increased hospital 
admissions and contribute to upward of 100 billion dollars in 
annual healthcare costs.5 
 
Reasons for medication non-adherence are many and broad 
6,7 and there are various types of interventions designed 
specifically to address non-adherence.8.9 McDonald and 
colleagues note, however, that “current methods of 
improving medication adherence for chronic health problems 
are mostly complex, labor-intensive, and not predictably 
effective.”10 
 
Therapeutic alliance is a concept that was described originally 
in the context of psychotherapy, but has since spread 
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throughout the healthcare community. Therapeutic alliance is 
broadly defined as a “collaborative bond” between a patient 
and a therapist11 although one no longer needs to be a 
therapist to develop this particular relationship with a 
patient. The therapeutic alliance is based on the premise that 
the healthcare provider and his or her patients are equals, 
with both parties making decisions and acting together 
toward common goals. Studies of therapeutic alliance in 
psychotherapy suggest that therapeutic alliance is predictive 
of better clinical outcomes.12  
 
With regard to therapeutic alliance in pharmacy practice, 
Berger emphasizes its importance and writes that 
“pharmaceutical care requires a much more intimate and 
intensive relationship between the pharmacist and patient 
than simple pharmaceutical dispensing.”13 Berger notes that 
pharmacist competence, trustworthiness, and caring are core 
of the therapeutic alliance between a pharmacist and his/her 
patients. More importantly, he notes that patients will be less 
likely to discuss medication problems with their pharmacist if 
patients perceive they will be judged or scolded for non-
adherence.14 Thus, pharmacists must appreciate their role is 
extending beyond dispensation and that therapeutic 
relationships with patients is both desirable and achievable. 
An indication of pharmacists’ positive attitudes towards 
therapeutic alliance is observed in one study that suggested 
80% of pharmacists believed that establishment of a 
therapeutic alliance was the highest priority in counseling, 
and 76% believed that “enhanced health outcomes would 
follow from mutual and cooperative interactions.”15 
 
The practice of pharmacy is indeed moving beyond mere 
dispensing of medications. Routinely, pharmacists are 
providing medication therapy management (MTM) services.16 
MTM refers to a range of pharmacist provided services that 
include the assessment of patients’ medications in order to 
achieve optimal medication regimens, improve adherence, 
enhance therapeutic outcomes, and reduce costs. MTM gives 
pharmacists the opportunity to identify and discuss 
medication-related problems, including medication non-
adherence and its numerous causes. 
 
To further explore the relationship between medication 
adherence and therapeutic alliance in the context of 
pharmacy practice, we undertook a study to investigate 
whether the administration of two brief scales, the Outcome 
Rating Scale (ORS) and the Session Rating Scale (SRS), by 
pharmacists providing MTM would increase medication 
adherence among their patients, thereby serving as a 
potential innovative strategy for enhancing the provision of 
MTM services by community pharmacists. Thus, we note that 
the use of the ORS and SRS would be an addition to the 
services already provided in MTM. 
  
The ORS and the SRS were developed and validated for use in 
psychotherapy as tools for monitoring and enhancing client 
outcomes and therapeutic alliance.17,18  Within this setting, 
the therapist uses client ratings from both scales to create a 
“client-directed and outcome- informed” process. Clients 
provide information on the scales, and therapists use that 
information to provide feedback both within a session and 
across sessions. The use of a continuous feedback system 
based on “practice-based evidence” (i.e., the data from the 
scales) can increase effectiveness and enhance outcomes. 
Results from one study where therapists used the ORS and 
SRS as a means of providing feedback with patients suggested 
greater and more efficient treatment gains than a “therapy-
as-usual” comparison group.19  Diabetes care managers have 
also successfully used the ORS and SRS with patients and 
have demonstrated improved diabetes-associated 
outcomes.20  
 
We believed that the use of the ORS and SRS in pharmacy 
practice might produce similar results as those shown in 
psychotherapy and would enhance the effectiveness of 
pharmacists’ clinical services. To implement the scales in the 
context of MTM, only one minor modification to one scale 
(SRS) was made: in one question the word “therapist” was 
changed to “pharmacist.”  All other questions were not 
changed, and we believed their reliability and validity was 
applicable to the clinical context of community pharmacist-
provided MTM services.  
 
Objectives 
We aimed to examine the relationship between therapeutic 
alliance and medication adherence in the context of 
pharmacy practice. The primary hypothesis was that patients 
who presented for MTM sessions with community 
pharmacists and received the ORS and SRS during the MTM 
sessions would show better medication adherence than 
patients who received MTM sessions but did not receive the 
ORS and SRS.  
 
Methods 
We collaborated with a national leader in MTM services who 
introduced us to a partnering pharmacy chain, Kerr Drug. Kerr 
Drug provides MTM services to Medicare Part D patients (per 
the MTM Core Elements, including services such as 
comprehensive medication reviews, prescriber consultations, 
patient compliance consultations, patient education and 
monitoring, physician collaboration and consultation and 
over-the-counter consulting).  Most of the patients receiving 
MTM services have chronic conditions such as diabetes, 
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hypertension, hyperlipidemia. Six pharmacists at Kerr Drug 
volunteered to participate in the study. The intervention was 
defined as the use of the two scales in the context of an MTM 
interaction where pharmacist and patient had the 
opportunity to communicate (e.g., during a comprehensive 
medication review or follow-up session). Pharmacists 
received a one-hour training in the administration and 
interpretation of the scales prior to project implementation. 
Patients could receive up to three interventions per the study 
protocol (to measure responses over time), however there 
were no criteria used to determine the number of 
interventions a patient would actually receive.  
 
The study protocol was approved by both the University of 
Pittsburgh IRB and Western IRB. Pharmacists invited their 
patients to participate in the study, and the patients were 
provided with an informational script detailing rights as a 
study participant. Patients provided consent verbally, as a 
waiver of signed consent was granted by WIRB. Patients 
could receive up to three MTM sessions per the study 
protocol. Based upon initial power calculations, the target 
enrollment for the intervention group was 200 patients. 
Study enrollment began in November, 2008, with the target 
enrollment number met on March 12, 2009. Data collection 
for the experimental group was completed on July 31, 2009.   
 
The study design called for pharmacists to provide the ORS 
and SRS within the context of MTM services. As such, scales 
could be administered “face-to-face” during MTM 
interactions or via telephone (if desired) during pharmacist- 
or patient-initiated follow-up sessions. The ORS was to be 
presented at the beginning of the MTM session and the SRS 
at the end of the session. Two versions of the ORS and SRS, 
written and oral, were made available to pharmacists and 
their patients and the version used was determined by 
patient preference.1
 
 For the written version, patients 
complete a visual analog scale, marking their scores with hash 
marks along a 10cm line for each of the four questions. There 
are no numbers on the scale; pharmacists use a ruler to 
measure the hash marks (from 0- 10cm) and note the score, 
where 1cm=1, 2cm=2, etc.  For the oral version, pharmacists 
read questions to the patients and patients provide responses 
on a scale from 1-10.  
The four items in the ORS ask patients to mark or rate from 1-
10 their quality of life in the following areas: Individually, 
Interpersonally, Socially, and Overall. The four items on the 
SRS ask patients to mark or rate from 1-10 the therapeutic 
                                                 
1 The written versions of the ORS and SRS are copyrighted 
materials. The oral version of the questions are presented in 
the Appendix. 
alliance with their pharmacist in the following areas:  Feeling 
heard, understood, and respected (Relationship); the patient 
having the opportunity to talk about or work on what the 
patient wants to talk about or work on (Goals and Topics), 
Approach or fit with the pharmacist (Approach and Fit), and 
the degree to which “something is missing in the session” 
(Overall).   
 
For each scale, there is a “clinical indicator” based on the 
total score (40) of each scale. A scale score below the clinical 
indictor (score of 25 on the ORS, score of 36 on the SRS) cues 
the provider to engage the patient and discuss the score in 
toto or in relation to a notably low item score. For example, 
on the SRS (the measure of therapeutic alliance), a patient 
may rate three of the four scale items with a “9”, but rate one 
item a “4”. The overall scale score would equal 31 and 
warrant further discussion, specifically (although not 
exclusively) to the item where the “4” was rated. So, if a 
patient rated the pharmacist a “4” in the Relationship 
category “feeling heard, understood and respected”), it 
would be necessary for the pharmacist to 1) note the rating 
at some point in the current or consequent interaction, 2) 
collaborate with the patient on ways to address and improve 
the rating and 3) re-measure at the next time point and 
assess the scores again. This feedback based process is used 
for both scales and across all 8 items. The main points are 
that 1) the pharmacist seeks to measure alliance and 2) used 
patient feedback as a means of improving alliance when 
applicable. 
 
After administering and interpreting the scores in the context 
of an MTM interaction, pharmacists then faxed the hard 
copies of the scales to the data collection center at the 
University of Pittsburgh.  Upon receipt, a confirmation email 
(including number of surveys received) was sent to 
pharmacists. Unclear or missing data were clarified or verified 
through email.  Data were then hand-entered into a 
Microsoft Access database and bimonthly reports were sent 
electronically to each pharmacist. All data were organized 
according to patient identification number. Pharmacists were 
to retain hard copies of the scales in patient charts or refer to 
the report as basis for follow-up discussion with patients.  
Patients could be seen for up to a total of three MTM 
sessions in order to assess scores over time/Again, there 
were no criteria established for additional sessions, other 
than pharmacist and patient willingness and/or availability.  
 
At the completion of the study, the list of enrolled patients 
was delivered to the MTM service provider for linkage of 
claims data within their system. Using this process, we were 
able to link 117 of the experimental group with claims data. A 
selection of comparable and de-identified claims data from 
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MTM service provider served as the comparison group 
(n=146). Pharmacy claims data for the study period were 
merged with individual MTM session data for both study 
groups.  Claims data were available from May 1, 2008 
through July 31, 2009.  We divided these data into two study 
periods of equal length:  before implementation of the 
project and after, to obtain a pre-scale implementation 
observation period that matched the follow-up time period.   
 
Our primary outcome measures were Proportion of Days 
Covered (PDC)21 and PDC80, where adherence is defined as a 
PDC of 80% or greater within a given interval.22 The 
denominator for the PDC for a particular medication was the 
total time between the first fill date for the medication within 
the study period and the end of the study period.  The 
numerator was the total days of supply within this same 
period.  The supply for the last prescription in a study period 
was capped at the last day of the period so that no PDCs were 
larger than 1.   
 
There is no a priori theory about therapeutic alliance (TA) 
having differential effect for adherence to different 
medications or by patients with different chronic illness. 
Therefore, our study included patients who were taking 
medications from at least one of three broad medication 
categories: antihypertensives (AH), antihyperlipidemics (AL), 
and antidiabetic (AD) agents (Table 1).  We defined our 
sample in two steps. The first step was subsetting to a sample 
with specific medication classes. We included these classes of 
medications because they are associated with chronic 
diseases states (hypertension, hyperlipidemia, and diabetes) 
often experienced by patients utilizing community 
pharmacist-provided MTM. For our analysis, we assumed that 
any switching between specific medications within the same 
class was not a reduction in persistence.  For example, a 
switch between atenolol and metoprolol was counted as one 
continuous prescription for purposes of calculating the PDC. 
We eliminated medications for which the patient only had 
one fill during the study period or patients whose claims 
record in either the baseline or follow-up period was less 
than 90 days.  Excluding these patients reduced our original 
sample sizes from 159 to 134 in the intervention group and 
178 to 156 in the comparison group. Our second step was to 
focus on a sample that had persistence in study medications 
in the periods before and after the study. This further 
reduced the samples of our intervention and comparison 
groups’ numbers of 117 and 146, respectively. Notably, the 
average PDC for individuals eliminated was above 99% within 
each study group and regardless of whether their only 
observation was in the prior or post period.   This similarity 
between the experimental groups implies a limited loss of 
differential treatment effect due to their exclusion.   
Alternative measures 
When patients had more than one qualifying medication, we 
averaged the PDC across the medications to produce an 
overall PDC and subsequent PDC80.  We also include in our 
analyses several alternative measures.  First, we calculated a 
Least-PDC measure that was the lowest PDC among a 
patient’s medications.  This allowed us to estimate the 
improvement in a patient’s least adhered-to medication.  We 
also constructed the Least-PDC80 measure in which the 
outcome was a dichotomous variable that indicated where 
the Least-PDC was greater than 80%.  An alternative way of 
thinking of the Least-PDC80 highlights its clinical significance: 
if a patient’s Least-PDC is greater than 80% then the PDC for 
each of that patient’s medications is greater than 80%, which 
is an ideal adherence outcome for these chronic diseases.   
 
We improved the accuracy and precision of our estimated 
effects by utilizing a double robust propensity score matching 
between our study groups and statistical modeling of 
improvements in our outcomes over time within patients.  
We compared baseline characteristics between our two study 
groups and analyzed their standardized differences23 in 
variables with the inclusion of propensity score weights in 
order to assess balance. Balance assessment determines the 
degree to which the statistics for covariates of non-random 
groups have been adjusted to seem more like covariates 
under randomization. A common heuristic for whether a 
measure is balanced is if the standardized difference is less 
than 10.24 Treatment effects for alternative outcomes were 
estimated.  We also explored how sensitive our analyses were 
to alternative propensity score matching methods and model 
specifications as well as sub-samples based on medication 
groups and trimming based on propensity scores.    
 
Propensity score matching allows us to adjust for observed 
patient characteristics that might have increased the 
likelihood of being in the treatment group.25-27 The propensity 
score is a patient’s probability of being in a specific treatment 
conditional on observed covariates. Conditioning on the 
propensity score match replicates some of the characteristics 
of a randomized controlled trial under certain assumptions.28 
Specifically, we estimated the probability of receiving TA-
enhanced MTM using time invariant (age gender, and 
indicator variables of whether the patient ever had a 
prescription fitting our three major medication categories) 
and baseline-only characteristics (PDC, PDC80, Lowest PDC, 
number of visits to the pharmacy, number of fills for any 
prescription medication, and number of unique study 
medications, and length of claims record prior to study 
implementation) and several alternative specifications with 
interactions of these variables and squares of the continuous 
variables.  All analyses were conducted using STATA 11 and 
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the DR and PSMATCH2 routines. We used standardized 
difference calculations29 to measure the improvement 
generated by propensity score matching (sample balance 
assessment).  
 
Our primary results are based on doubly robust propensity 
score models which combine standard inverse propensity 
score weighting and multivariate statistical modeling.   This 
method is particularly useful for circumstances when there is 
continued imbalance in baseline measures, even after 
adjusting and re-adjusting balance. With a well-specified 
model, the method provides unbiased estimates of the effect 
of a treatment.30 This approach also overcomes differences in 
outcomes prior to the intervention.  With a simple post-
intervention comparison of differences between groups or 
differences-in-differences estimation of TA’s effect could be 
biased.  Model-based estimates of TA’s effect that included 
baseline dependent variables as controls could help reduce 
the bias but are themselves limited by the range of the 
outcomes. For example, we observe that the PDC80 is closer 
to 100% for the MTM group than for the MTM+TA group.  
Any spurious improvement (e.g., regression to a mean 
adherence level) will necessarily be smaller for the MTM than 
the MTM+TA group and would lead to an upward bias on the 
estimated effect of TA.  We report the differences-in-
differences results alongside our propensity score model 
results for comparison.  For the binary outcome of PDC80, we 
employed a generalized linear model with a probit link 
function.  For continuous PDC standard regression is used.  In 
this manner, we gain the benefits of a comparison group, 
reduce bias from selection into treatment, and control for 
baseline outcomes and other characteristics.  When 
estimating these models for the subpopulations based on 
medication group, we include both the specific medication 
group PDC and the overall PDC measures as baseline 
covariates in order to control for all the information 
describing a patients behavior regarding adherence. 
 
Results  
Six pharmacists participated in the study. Five (83%) are 
female and one (17%) is male. Other pharmacist 
characteristics and location of pharmacies (e.g., urban, 
suburban, rural) were not recorded. Pharmacists enrolled 
patients in twenty-eight (28) pharmacies.  The mean number 
of stores covered by pharmacists was approximately 4.7 
(range 2-7), and the mean number of patients seen by each 
pharmacist was 34 (range 5-60). We note the attrition of two 
participating pharmacists who left their pharmacies for other 
pursuits during the course of the study. The total number of 
participants enrolled was 201. Consequently, 134 participants 
(66.7%) received a second session, and 73 participants 
received a third session (36.3%). In order to alleviate survey 
burden, we did not collect any demographic data other than 
age and gender. More than two-thirds (70%) of the study 
sample were females. After matching with claims data, the 
direct intervention group was n=117, with an average age of 
76.4. The comparison group was n=146, with an average age 
of 76.2.  Anecdotally, pharmacists reported that patient 
ethnicity included, primarily, African-Americans, Caucasians, 
and Native Americans. 
 
Main Outcomes 
Propensity Score Adjustment Results 
At baseline, demographic differences were minimal between 
the MTM+TA (N=117) and MTM (N=146) groups.  Table 2A 
shows the unadjusted and inverse propensity-score weighted 
summary statistics for the two experimental groups.    The 
two groups exhibit little difference in their interactions with 
the pharmacies during the 9 months prior to the 
implementation of the intervention.  They both had roughly 
20 visits and 37 fills for any medication.   Likewise, both 
groups had prescriptions for an average of 3.1 unique study 
medications, counted by having had at least one fill for a 
prescription. 
 
The statistics we present here for medications do not 
correspond directly with the included medications in our key 
outcome variables (PDC and PDC80), but they help to 
demonstrate potential differences in our study samples.  Thus 
they are used in our propensity score model and as controls 
in the multivariate model because they are correlated with 
unobserved patient characteristics that could bias our 
estimates of TA’s impact. For individual medication categories 
the two groups were similar. For example, around 89% of 
patients had at least one fill for an anti-hypertensive 
medication (not including combination medications that 
included an anti-hypertensive). There were differences in the 
prevalence of having filled at least one prescription from 
more than one medication category, although these were not 
statistically significantly different.  For all of these pre-
interventions patient characteristics we note the 
standardized differences before and after propensity score 
weighting.  With the exception of the number of fills for anti-
hypertensive and anti-diabetic medications the differences 
were less than 10 and for both of these exceptions the 
differences did decrease with the inclusion of weights.   
 
Table 2B continues the comparison of the two study groups 
and focuses on the key outcomes PDC80 and PDC prior to 
implementation of TA.  There is little difference between the 
study groups for days in the claims record.  This variable 
represents the total time for which we have a record on a 
patient during the baseline period and is measured by 
subtracting the date of their first claim from the date of their 
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first MTM session during the TA implementation period.  It 
provides a sense of the overall time for which we have data 
on patients during which we could measure their adherence.  
It is not necessarily the denominator for PDC calculations 
since those denominators are medication specific and are 
defined according to measurement rules defined in the 
methods section.  
 
Baseline PDC80 is significantly different for the two study 
groups with the MTM group at 97.3 versus 88.9 for the 
MTM+TA group.  Similarly, the MTM+TA group has a 
statistically significantly lower PDC, although the difference is 
much smaller (91.2 versus 94.5).  The same pattern of worse 
baseline outcomes for the MTM+TA group holds for LeastPDC 
outcomes. The last column of Table 3 provides results for a 
comparison between the two groups using only their 
outcomes after the implementation of TA.  This calculation 
ignores baseline values and thus the relative improvement 
over time.  Again, the results are consistent with TA 
improving outcomes.  Only PDC80 is not significant at the 
p<.1 level, though its magnitude is not small and its sign is 
positive.  This is still suggestive of an effect, since when the 
groups are already close to PDC80 of 100% there is little room 
for relative differences.  The final column combines the 
‘within group’ and ‘across group’ differences and thus 
compares the relative improvements over time and finds 
large and significant effects for TA for all outcomes.  Finally, 
we note that both the total days in the claims record and the 
denominators for calculating PDC do not vary significantly 
across our study groups improving our confidence that any 
improvement in PDC outcomes is due to improved adherence 
rather than superficial differences in lengths of medication 
persistence.  Moreover, it is noteworthy that TA did not lead 
to significant changes in how long patients persisted in 
medications.   
 
Although Table 3 is suggestive of TA having a positive effect, 
we feel that the use of the doubly robust approach is well 
justified and we expect significantly reduces bias due to our 
quasi-experimental design.  Any selection into the TA group is 
arguably correlated with observable characteristics such as 
poorer adherence that can be alleviated using propensity 
score weighting while the doubly robust framework still 
permits the multivariate model with baseline adherence 
variables and other controls.  Indeed the last three columns 
of Table 2B show substantial improvement in the balance 
between the two samples due to propensity score weighting.  
The PDC80 are closer (94.4 versus 93.7) with a relatively low 
standardized difference of 3.1.  Differences in baseline 
adherence measures improve for all measures and all 
standardized differences are less than 10 except for Least-AH-
PDC80 and Least-AL-PDC80. 
Main effects 
Table 4 reports the primary effectiveness results from our 
double robust model of outcomes.  We found that 
MTM+TA led to a PDC80 rate that was 4.6 percentage points 
higher than MTM alone (97.0 versus 92.4).  The effect was 
statistically significant at p=.020.  Stated alternatively, 
MTM+TA had an average treatment effect of 4.6 on the rate 
of PDC80, or a roughly 4.9% improvement over no treatment.  
This improvement is consistent with the improvement seen 
for PDC, the continuous latent variable that is used to 
determine PDC80. PDC increased by 3.1 percentage points 
from 93.9 to 97.0 (p<.01).   
 
We next report the average treatment effect for each 
patient’s lowest PDC medication. The LeastPDC80 improved 
by 13.2 percentage points (17.6%, 88.5 versus 75.2) and was 
statistically significant (p<.01).  The alternative interpretation 
of this is that TA yields 13.2 percentage points more patients 
who achieved a PDC of 80% for all study medications.  The 
average treatment effect on the underlying PDC was 5.9 
percentage points (p<.001; 93.2 versus 87.3). 
 
Discussion 
Our findings support the notion that pharmacists and 
patients do indeed enter into a therapeutic relationship, 
similar to those found in relationships between patients and 
other types of healthcare professionals (e.g., 
psychotherapists or physicians) and that enhancing this 
relationship can result in significant improvements in patient 
health behavior and consequently, improvements in the 
overall effectiveness of MTM encounters. While the 
evaluation of some clinical pharmacy programs has found 
improvements in medication adherence,31 it is encouraging 
that we found further improvements in adherence in our 
intervention sample, as compared to when pharmacists 
delivered MTM per usual practice. This points to the 
importance of the pharmacist-patient relationship. 
 
Specifically, our findings demonstrate that providing 
community pharmacists with a method of measuring their 
therapeutic alliance with patients throughout the course of 
MTM services is associated with a significant improvement in 
patient medication adherence.  We believe this is because 
measuring therapeutic alliance enables the pharmacist to 
appropriately focus his or her interventions to ensure that 
they are provided from the perspective of what the patient 
may need; that is, the focus of the intervention is both client-
directed and outcome-informed.  Based on this study, we 
believe that measurement of the therapeutic alliance enabled 
the pharmacist to more effectively understand and respond 
to patients’ medication-related needs and, as a result, 
successfully promote patient adherence to medications. 
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Our findings are also important because they demonstrate 
the utility of a “low intensive” intervention, in terms of time 
and resources required.  Pharmacists in the study were able 
to implement use of the ORS and SRS scales in their MTM 
practice after only about one hour of training, and 
administration of the scales required only about two minutes 
per visit.  This ease of implementation may contribute to 
improved sustainability of this approach to enhancing MTM 
practice as compared to other interventions that may be 
proposed. The implementation of the ORS and SRS scales in 
MTM practice may also benefit from a “clinical supervision” 
model, via a management structure that supports its 
application by all clinical staff.  As an example, a clinical 
supervisor, via a review of the pharmacist’s ORS/SRS scores 
for specific patients and across patients, may suggest ways 
that the pharmacist might improve his/her alliance with any 
given patient or might even suggest that a specific patient be 
transferred to another pharmacist within the practice when 
the alliance fails to develop.  Evaluation of this clinical 
supervision model (i.e., using the ORS/SRS scores to make 
practice changes for the pharmacist) could be another fruitful 
area for further research. 
 
As noted earlier, using the ORS and SRS may also improve the 
effectiveness and efficiency of a patient’s MTM visit.  For 
example, discussions around the ORS and SRS may reveal the 
“real” reasons for a patient’s non-adherence sooner and may 
allow the pharmacist to respond to the individual needs of 
the patient at an earlier visit, rather than first trying an 
intervention because it is what is assumed that the patient 
needs.  This may result in more immediate improvements in 
adherence. During informal interviews that we conducted 
with the participating pharmacists, it was noted that the 
scales helped differentiate the perceived reasons for patient 
non-adherence and other medication-related problems from 
the actual cause.  As one pharmacist said: 
 “I found that using these instruments helped me 
focus on what the patient needs instead of a 
medication list or what I think they need.  It has 
caused me to think ‘out of the box’ in ways that I did 
not realize I could.”32  
An example of this that pharmacists might see in their 
practice would be if one makes the assumption that 
nonadherence is due to patient forgetfulness but it was 
actually a result of patient concerns regarding medication 
side effects, psychosocial problems that were overwhelming 
the patient, duplicative prescribing of specific medications by 
different physicians or an inability to afford the cost of the 
medication.  The same pharmacist said:   
“One patient told me she was very tired…I found this 
out when I questioned her from the ORS…it turns 
out she is taking 4 sedatives throughout the day 
prescribed by three physicians…much more than she 
should be…I spoke with her PCP [primary care 
physician] and we changed her regimen.”   
Another pharmacist reported that using the scales allowed 
her to change her practice through actively listening to her 
patients.33 The use of the ORS and SRS focuses on the 
measurement of patient outcomes and therapeutic alliance, 
although it is clear from these examples that the simple act of 
measurement lends itself in the short term to opening up a 
productive dialogue between pharmacists and patients. 
Pharmacists can use the information from the ORS to inquire 
and guide their interactions with patients to address patient 
outcomes, and then use the information from the SRS to 
ensure that they are doing so in a manner the patient 
perceives as beneficial. While adherence was an important 
outcome measure for the purpose of this study, the use of 
the scales is indeed flexible to address any number of MTM-
related issues that may appear.  
 
It is also clear from pharmacist responses that there is a great 
potential for pharmacy practice change. Given the empirical 
foundation for the use of the scales, as well as their clinical 
utility and real world feasibility, we believe teaching the use 
of the scales in pharmacy schools could avail future 
generations of pharmacists with the necessary skills to 
reliably and effectively address patient needs and concerns. 
 
Limitations 
There are a few limitations to the study.  First, we note 
administration variations described in the protocol were not 
recorded and may have had some bearing on the results. 
Specifically, pharmacists could provide the scales during face-
to-face MTM sessions or they could administer the scales via 
telephone calls. We did not track which scales were 
administered in person or via the telephone so this variable 
was not included in our analyses. Further research is 
warranted to better understand the impact that the care 
delivery method has on the use of these scales and related 
changes in medication adherence. 
 
Second, we did not collect any participant demographic 
information other than gender and age so generalizability of 
our findings across patient populations is limited. The average 
age of the study sample was ~75 years old and the majority of 
participants were female. The results of our study should be 
considered specific to this particular sample of participants, 
although future studies would investigate the use of these 
scales with participants from a wider age range.  Anecdotally, 
pharmacists reported that patient race included African-
American, Caucasian, and Native American, but future studies 
would include participant self-report of comprehensive 
demographic information, including race and ethnicity, level 
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of education, and socio-economic status, to name a few. At 
this time, any variation in adherence changes due to these 
demographic factors is unknown. 
 
Third, the random selection of comparison group data did not 
include any information about pharmacist characteristics. 
Therefore, we were unable to assess similarities or variations 
in pharmacist characteristics as variables for consideration in 
the analysis.  We also did not examine differences in 
adherence among patients seen by different providers and 
we did not determine the impact of changing providers, as for 
the purposes of this study, patients were seen by the same 
pharmacist at each of their study-related MTM visits.  As 
described earlier, a model that includes feedback to facilitate 
adjustments in provider-patient pairing may be useful and 
the use of these scales should be further evaluated in this 
type of setting.   
 
Fourth, we also only examined adherence data for a few 
specific classes of medications.  It is unknown if the use of the 
scales is related to improvements in adherence to other 
medications.  Further, the actual indication of prescribed 
medications in this study is unknown; therefore, while we 
expect that improvements in this study would be related to 
improvements in clinical outcomes such blood pressure, LDL-
cholesterol, and blood glucose, this is unknown as some 
medications indicated for hypertension, hyperlipidemia, and 
diabetes are also commonly used to treat other conditions.  
Future studies that examine the impact of therapeutic 
alliance measurement on clinical outcomes are needed.  In 
addition to relevant clinical markers listed above, these 
evaluations should examine whether the use of these scales 
positively impacts long-term outcomes, including emergency 
room visits and hospitalizations associated with common 
chronic diseases addressed in MTM sessions.  While our 
qualitative comments suggest this is the case, future research 
efforts could also examine whether the use of the ORS and 
SRS improve patient satisfaction with pharmacist-provided 
MTM and whether pharmacists using these scales are more 
confident in their ability to provide MTM and respond to their 
patients’ medication-related needs.  Each outcome would 
provide further argument for the routine use of these scales 
in pharmaceutical care.  
 
Finally, limitations of pharmacy refill records as the data 
source for adherence assessments have been described.34 
Therefore, while our findings demonstrate improved 
adherence as measured by claims data, further assessments 
of MTM programs using the therapeutic alliance scales that 
include alternate methods for adherence measurement may 
be warranted.  Examining medication adherence at sustained 
intervals beyond that measured in the current study (e.g., at 
one or more years post implementation of the scales by the 
pharmacists) is also warranted. 
 
Conclusions 
Providing pharmacists with a mechanism for measuring their 
therapeutic alliance with patients receiving MTM services 
was associated with improvements in medication adherence.  
Implementing the study intervention required relatively little 
resources, suggesting that the use of these scales may be a 
feasible and effective strategy for enhancing the impact of 
community pharmacist-provided MTM services.  Additional 
research is needed to examine the impact of these scales in 
different patient populations and in various care settings and 
future studies would include a randomized clinical trial to test 
the efficacy of this intervention with a larger sample.  In 
addition to considering the impact of the scales on 
adherence, these evaluations could include measurements of 
both clinical outcomes (e.g., hospitalizations) and humanistic 
outcomes such as patient satisfaction with MTM and 
pharmacists’ confidence in providing MTM services in ways 
that address patients’ medication-related needs. 
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Appendix 
 
Outcome Rating Scale Items 
On a scale from 1 to 10, where 1 is “bad” and 10 is “good”: 
1. How have you been doing personally? 
2. How have things been going in your relationships? 
3. How have things been going for you socially? 
4. How would you rate how things in your life are going overall? 
 
Session Rating Scale Items 
1. On a scale of 1-10, to what degree did you feel heard and understood today, 10 being     
    completely and 1 being not at all? 
2. On a scale of 1-10, to what degree did we work on the issues that you wanted to     
    work on today, 10 being completely and 1 being not at all?  
3. On a scale of 1-10, how well did my approach, the way I worked, make sense and fit  
    for you? 
4. So, given your answers on these specific areas, how would you rate how things were in  
    today’s session overall, with 10 meaning that the session was right for you and 1  
    meaning that something important that was missing from the visit? 
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TABLES 
    Table 1. Medication Classes Included in Adherence Analyses 
 
Antihypertensives Antidiabetics Antihyperlipidemics 
          ACE-inhibitors 
          Calcium-Channel Blockers 
          Beta-Blockers 
          Thiazide Diuretics 
          Angiotensin-Receptor      
                 Antagonists 
          Potassium-Sparing Diuretics 
          Loop Diuretics 
          Renin Inhibitors 
          Alpha-2 Agonists 
          Vasodilators 
          Alpha-Blockers 
          Mixed Alpha/Beta Blockers 
          Various combination products  
         (VCPs) 
          Biguanides 
          Thiazolidinediones 
          Sulfonylureas 
          Meglitinides 
          DPP-IV Inhibitors 
          Incretin Mimetics 
          Insulins 
          VCPs 
 
        
          Bile acid sequestrants 
          HMG Co-enzyme-A- 
                Reductase Inhibitors 
          Fibric Acid Derivatives 
          Niacin 
          Ezetimibe 
          Omega 3 
          VCPs 
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Table 2A. Baseline Characteristics of Patients Who Were Observed Before and After the Implementation of Therapeutic 
Alliance:   By Experimental Group 
Variable Percent/Mean (StDev) 
Standardized 
Difference 
P-
value1 
  
  
  
Percent/Mean (StDev) Standardized Difference 
 
Unadjusted Propensity Score Adjusted  
MTM 
Only 
(N=146) 
MTM + 
Therapeutic 
Alliance 
(N=117) 
    
MTM 
Only 
(N=146) 
MTM + 
Therapeutic 
Alliance 
(N=117) 
  
Female(%) 
78.1 70.1 18.26 0.126 76.1 74.8 3.10 
(41.51) (45.99) 
  
(42.77) (43.61) 
 
  
Age 
(Years): 
All 
76.2 76.4 2.87 0.721 76.2 76.1 2.20 
(6.96) (6.69) 
  
(6.81) (6.60) 
 
 
Female 
75.4 76.6 18.82 0.143 75.9 75.7 2.00 
(6.24) (6.76) 
  
(6.24) (6.48) 
 
Male 
78.9 75.8 41.26 0.094 77.3 77.1 3.72 
(8.62) (6.58) 
  
(8.37) (6.98) 
 
No. of Visits to the 
Pharmacy 
20.5 20.3 1.56 0.944 20.8 20.4 3.33 
(10.86) (11.98) 
  
(10.84) (11.81) 
 
No. of  Fills for 
Any Medication 
36.5 37.0 2.64 0.765 37.4 36.7 3.55 
(19.16) (22.06) 
  
(19.11) (21.73) 
 
No. of Study 
Medications 
3.1 3.1 0.12 0.889 3.2 3.1 3.11 
(1.65) (1.70) 
  
(1.64) (1.74) 
 
Any Fills for 
Hypertension 
Medications (%) 
89.0 89.7 2.27 0.654 90.9 90.4 1.55 
(31.35) (30.47) 
  
(28.93) (29.59) 
 
Any Fills for 
Hyperlipidemia 
Medications (%) 
56.8 53.8 6.02 0.665 56.9 56.0 1.74 
(49.70) (50.07) 
  
(49.69) (49.85) 
 
Any Fills for Two 
Medication 
Categories (%) 
41.8 48.7 13.92 0.153 44.4 43.8 1.27 
(49.49) (50.20) 
  
(49.86) (49.83) 
 
Any Fills for All 
Three Medication 
Categories (%) 
29.5 23.9 12.46 0.428 28.7 27.9 1.68 
(45.74) (42.85) 
  
(45.40) (45.07)   
1 - Based on Chi-Squared tests for dichotomous variables and T-tests for continuous variables 
2 - Does not include combination medications. 
Baseline Characteristics of Patients Who Were Observed Before and After the Implementation of Therapeutic Alliance:  By 
Experimental Group 
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Table 2B. Baseline Characteristics of Patients Who Were Observed Before and After the Implementation of Therapeutic Alliance: By 
Experimental Group 
Variable Percent(StDev) 
Standardized 
Difference 
P-value1 
  
Percent(StDev) 
Standardized 
Difference 
Unadjusted Propensity Score Adjusted  
 
MTM Only 
(N=146) 
MTM + 
Therapeutic 
Alliance (N=117) 
  
MTM Only 
(N=146) 
MTM + 
Therapeutic 
Alliance 
(N=117) 
 
Days in 
Claims 
Record 
187.3 185.8 5.66 0.605 187.3 186.5 3.21 
(27.75) (23.60) 
  
(27.58) (21.86) 
 
PDC80 
97.3 88.9 33.29 0.006 94.4 93.7 3.12 
(16.38) (31.56) 
  
(23.08) (24.48) 
 
PDC 
94.5 91.2 40.58 0.000 93.4 93.2 3.18 
(6.30) (9.68) 
  
(7.50) (8.03) 
 
Least-
PDC80 
79.3 69.6 22.39 0.006 75.2 76.3 2.55 
(40.65) (46.21) 
  
(43.35) (42.73) 
 
Least-PDC 
89.2 84.6 34.16 0.006 87.8 87.0 5.83 
(12.15) (14.85) 
  
(13.19) (13.63) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Original Research PRACTICE-BASED RESEARCH 
 
http://z.umn.edu/INNOVATIONS                              2011, Vol. 2, No. 1, Article 33                   INNOVATIONS in pharmacy   15 
 
Table 3. Comparison of Study Outcomes Over Time and by Study Group 
 
MTM 
 
MTM+TA 
 
 
 
Mean (St. Err.) 
Mean, p-
value 
Mean (St. Err.) Mean, p-value Estimate, p-value 
 
Before After Difference Before After Difference 
Post Only 
Differences  
Difference in 
Differences 
   
PDC80 
97.3 96.6 -0.7 88.9 99.1 10.3 2.5 
 
10.9 
(1.4) (1.5) .735 (2.9) (0.9) .001 .021 
 
.008 
   
PDC 
94.5 94.4 -0.1 91.2 96.8 5.6 2.4 
 
5.8 
(0.5) (0.5) .854 (0.9) (0.4) .000 .000 
 
.000 
   
Least-PDC80 
78.8 78.1 -0.7 70.1 88.9 18.8 10.8 
 
19.5 
(3.4) (3.4) .887 (4.3) (2.9) .000 .001 
 
.001 
   
Least-PDC 
89.2 88.0 -1.2 84.6 92.9 8.3 4.9 
 
9.5 
(1.0) (1.0) .394 (1.4) (0.8) .000 .000 
 
.000 
   
Days in Claims 
Record 
187.3 208.3 21.0 185.8 209.3 23.5 1.0 
 
2.4 
(2.3) (1.9) .000 (2.2) (1.4) .000 ..613 
 
.532 
   
Denominator 
181.8 200.1 18.4 179.6 200.3 20.8 .2 
 
2.4 
(2.9) (2.7) .000 (2.9) (2.4) .000 .466 
 
.363 
   
Notes: p-values were calculated using t-tests for continuous variables and chi-squared tests for binary outcomes.  P-values for the 
difference in differences were calculated within a repeated measures GEE. 
 
Original Research PRACTICE-BASED RESEARCH 
 
http://z.umn.edu/INNOVATIONS                              2011, Vol. 2, No. 1, Article 33                   INNOVATIONS in pharmacy   16 
 
 
Table 4. Doubly Robust Estimates of the Effect of MTM+TA 
 
Doubly Robust 
Estimated Outcome 
(Percent) 
 
Doubly Robust Average 
Treatment Effect  
MTM 
MTM + 
TA 
Percentage 
Point 
Difference, 
p-value 
Percent 
Difference 
 
PDC80 92.4 97 
 
4.6 
0.020 4.98 
 
PDC 93.9 97 
 
3.1 
0.000 3.30 
 
Least-
PDC80 
75.2 88.4 
 
13.2 
0.004 17.55 
 
Least-
PDC 
87.3 93.2 
 
5.9 
0.000 6.76 
 
 
